Accès ouvert
2026
article
OpenAlex
Jianguo Huang, Xingliang Liu, Warren Floyd, William Haugh et autres
Undifferentiated pleomorphic sarcoma (UPS) is one of the most common adult soft-tissue sarcomas (STSs), yet therapeutic progress remains limited because of the absence of recurrent oncogenic driver mutations. To identify tumor suppressors contributing to UPS pathogenesis, we performed a customized in vivo …
us, cn, ca
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Traci L. Hilton, Ryan Meng, Guo Hui Gan, Tarsem Moudgil et autres
Abstract Background: Despite advances in cancer genomics and immunotherapy, most cancer vaccine strategies target a limited set of canonical or mutated cancer antigens, capturing only a fraction of tumor antigenicity. Malignant cells generate a vast, largely unexplored repertoire of non-canonical “dark matter” …
us, jp
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Venkatesh Rajamanickam, Noah D. Simons, Wesley K. Rosales, Anton Kravchenko et autres
Improving responses to neoadjuvant therapy for patients with locally advanced rectal cancer has the potential to improve organ preservation and disease-free survival. Knowing which patients may need therapeutic escalation or de-escalation from standard-of-care treatment remains an area of investigation. We previously reported …
us, gb, co
(code pays fourni par la source)
Accès ouvert
2018
article
OpenAlex
Vésteinn Thórsson, Vésteinn Thorsson, David L. Gibbs, Scott D. Brown et autres
We performed an extensive immunogenomic analysis of more than 10,000 tumors comprising 33 diverse cancer types by utilizing data compiled by TCGA. Across cancer types, we identified six immune subtypes-wound healing, IFN-γ dominant, inflammatory, lymphocyte depleted, immunologically quiet, and TGF-β dominant-characterized by …
us, ca, es, be, qa, br
(code pays fourni par la source)
Accès ouvert
2014
article
OpenAlex
John N. Weinstein, Rehan Akbani, Bradley McIntosh Broom, Wenyi Wang et autres
Urothelial carcinoma of the bladder is a common malignancy that causes approximately 150,000 deaths per year worldwide. So far, no molecularly targeted agents have been approved for treatment of the disease. As part of The Cancer Genome Atlas project, we report here …
us, ca
(code pays fourni par la source)
2008
conference-paper
OpenAlex
Brady Bernard, Ram Samudrala, Mehmet Sarıkaya, Candan Tamerler et autres